Last reviewed · How we verify

Cystic Fibrosis — Treatment Landscape & Competitive Intelligence

Cystic Fibrosis (Respiratory) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Respiratory 4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cystic Fibrosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Alyftrek VANZACAFTOR Vertex Pharms Inc Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] 2026-01-01
Trikafta (Copackaged) ELEXACAFTOR Vertex Pharms Inc Cystic fibrosis transmembrane conductance regulator 2019-01-01
Pulmozyme DORNASE ALFA Roche Recombinant Human Deoxyribonuclease 1 [EPC] 1993-01-01
Mannitol Mannitol Baxter Osmotic diuretic Glomerular filtrate osmolarity; intracellular water movement 1964-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 2 drugs in Cystic Fibrosis
  2. Vertex Pharms Inc · 2 drugs in Cystic Fibrosis
  3. Roche · 1 drug in Cystic Fibrosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cystic Fibrosis:

Cite this brief

Drug Landscape (2026). Cystic Fibrosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cystic-fibrosis. Accessed 2026-05-17.

Related